9Q8L

Crystal Structure of 21A08Ap1-Fab in Complex with Human PD-1 at 1.85 angstrom Resolution

Summary for 9Q8L

• Entry DOI: 10.2210/pdb9q8l/pdb
• Descriptor: Heavy chain of huIgG1-Fab, Light chain of huIgG1-Fab, Programmed cell death protein 1, ... (9 entities in total)
• Functional Keywords: pd-1, immune checkpoint, fab, huigg1, 21a08ap1, t-cells, immune system
• Biological source: Mus musculus; More
• Total number of polymer chains: 3
• Total formula weight: 64077.03

Authors

Murer, P.,Petersen, L.,Egli, N.,Salazar, U.,Neubert, P.,Zurbach, A.,Rau, A.,Stocker, C.,Katopodis, A.,Huber, C.,Carr, K.,Arduin, A. (deposition date: 2025-02-25, release date: 2025-08-13)

Primary citation

Murer, P.,Petersen, L.,Egli, N.,Salazar, U.,Neubert, P.,Zurbach, A.,Rau, A.,Stocker, C.,Reichenstein, D.,Katopodis, A.,Huber, C.
ANV600 is a novel PD-1 targeted IL-2R beta gamma agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.
J Immunother Cancer, 13:-, 2025

PubMed Abstract: Combining interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has shown synergistic potential in reinvigorating antitumor T cell responses. However, integrating these two mechanisms within a single molecule has been challenging due to competing requirements for PD-1 engagement and IL-2 receptor signaling. ANV600 is a novel bispecific antibody-cytokine fusion protein that targets a non-blocking epitope on PD-1, enabling -targeted IL-2Rβγ agonism while preserving combinability with therapeutic PD-1 inhibitors. This design allows for selective expansion of tumor antigen-specific T cells while avoiding the systemic toxicity and regulatory T cell (Treg) expansion associated with conventional IL-2 therapies.

PubMed: 40664449
DOI: 10.1136/jitc-2025-011905

Experimental method

X-RAY DIFFRACTION (1.85 Å)